ChemLifeIntelCHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
REGULATORY INTELLIGENCERecallHigh Severity

Critical Class I Recall: TCP HRB ACQUISITION LLC's Sure Anti-perspirant Contaminated with Benzene, Impacting US and Canada

MK
Meera KrishnanView Profile →
Senior Regulatory Intelligence Analyst
EXECUTIVE SUMMARY

TCP HRB ACQUISITION LLC has initiated a Class I recall for 0.5 million units of Sure Unscented Anti-perspirant Deodorant Aerosol across the US and Canada due to benzene contamination. This high-severity event, identified on February 16, 2022, demands immediate action from procurement and regulatory teams to assess supply chain vulnerabilities, enhance quality control, and mitigate significant market disruption risks from similar chemical contamination issues.

Immediate Business Impact of TCP HRB ACQUISITION LLC's Class I Benzene Contamination Recall

On February 16, 2022, TCP HRB ACQUISITION LLC, based in Westport, CT, initiated a Class I recall for its Sure Unscented Anti-perspirant Deodorant Aerosol, specifically products containing Aluminum Chlorohydrate 10%. This recall, identified as D-0208-2024, is of the highest severity, indicating a reasonable probability of serious adverse health consequences or death due to the presence of benzene, a known human carcinogen. For procurement directors and regulatory affairs heads, this means an immediate re-evaluation of product safety profiles and supplier reliability for all aerosol personal care items. The recall encompasses 0.5 million units, distributed nationwide across the United States and Canada, affecting all lots with an expiry on or before August 2023. The product, packaged in 6 oz (170 g) aerosol cans, was distributed by Idelle Labs, Ltd., El Paso, TX. This voluntary, firm-initiated action, publicly announced via a press release, underscores the critical need for robust quality control throughout the entire supply chain, from raw material sourcing to finished product distribution. Businesses must understand that a Class I recall of this magnitude not only carries significant financial implications from product retrieval and destruction but also severe reputational damage, impacting consumer trust and market share for the Sure brand and potentially the broader anti-perspirant category.

Supply Chain Vulnerabilities and Market Repercussions from Contaminated Aerosol Deodorants

The recall of 0.5 million units of Sure Unscented Anti-perspirant Deodorant Aerosol due to benzene contamination highlights profound vulnerabilities within the personal care product supply chain. For supply chain VPs, the widespread distribution across both the US and Canada signifies a complex logistical challenge in retrieving affected products. The fact that Idelle Labs, Ltd. was the distributor, while TCP HRB ACQUISITION LLC initiated the recall, points to potential complexities in manufacturing and distribution agreements, demanding clarity on responsibility for quality assurance at each stage. Benzene contamination, particularly in aerosol products, often originates from propellants like butane, propane, or isobutane, or other raw materials. This incident necessitates that procurement teams scrutinize their entire bill of materials for aerosol products, extending beyond active ingredients like Aluminum Chlorohydrate to include all excipients and packaging components. The market impact extends beyond direct financial losses; it creates a ripple effect of consumer distrust in aerosol formats and specific brands. Competitors who can demonstrate superior quality control and robust testing for contaminants like benzene may gain a competitive advantage, forcing affected companies to invest heavily in re-establishing brand credibility and market position. This event serves as a stark reminder that even seemingly minor components can trigger major recalls, disrupting market supply and demanding costly remediation efforts.

Heightened Regulatory Scrutiny and Industry Standards for Benzene in Personal Care Products

The FDA's classification of this event as a Class I recall due to benzene contamination signals a heightened regulatory environment for personal care and over-the-counter (OTC) drug products. Benzene, classified as a human carcinogen, has been a recurring issue in various consumer products, leading to increased scrutiny from regulatory bodies like the FDA. For regulatory affairs heads, this incident underscores the imperative to proactively review and update internal quality management systems (QMS) and supplier qualification programs. The industry has witnessed a trend of contamination-related recalls, emphasizing the need for robust analytical testing beyond routine specifications, particularly for trace impurities in raw materials and finished goods. Companies must ensure their contract manufacturing organizations (CMOs) and raw material suppliers adhere to stringent good manufacturing practices (GMPs) and conduct comprehensive impurity profiling. The FDA expects firms to identify the root cause of such contamination, implement effective corrective and preventive actions (CAPAs), and provide evidence of their efficacy. Failure to demonstrate adequate control over product quality and safety can lead to further enforcement actions, including additional recalls, import alerts, or even facility inspections, significantly impacting a company's ability to operate in regulated markets. This recall reinforces that regulatory compliance is not merely a checkbox exercise but a continuous commitment to public health and product integrity.

Proactive Risk Mitigation Strategies for Procurement and Quality Assurance in Aerosol Formulations

In response to the TCP HRB ACQUISITION LLC recall, procurement directors and business development executives must implement proactive risk mitigation strategies to safeguard their supply chains and product portfolios. First, a comprehensive audit of all suppliers providing propellants, solvents, and other raw materials for aerosol formulations is critical. This audit should specifically assess their testing methodologies for benzene and other volatile organic compounds (VOCs), demanding Certificates of Analysis (CoAs) that include impurity profiles. Second, establishing robust in-house or third-party analytical testing capabilities for incoming raw materials and finished products can serve as an essential safeguard, moving beyond reliance solely on supplier documentation. Third, diversification of the supplier base for critical components, such as Aluminum Chlorohydrate and aerosol propellants, is paramount. Relying on a single source increases vulnerability to quality issues and supply disruptions. Companies should identify and qualify alternative manufacturers, considering geographic diversity to mitigate regional risks and ensure continuity of supply. Finally, business development teams should leverage this event to differentiate their products by emphasizing superior quality control, transparent testing, and a commitment to consumer safety. This proactive approach not only minimizes the risk of future recalls but also strengthens market position by building trust and demonstrating leadership in product integrity.

ChemLifeIntel analysis · Meera Krishnan. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — covering 1,200+ pharmaceutical and chemical companies across the global value chain.

Covering 1,200+ pharmaceutical and chemical companies across the global value chain
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
3d ago

CDSCO Enacts Sweeping Regulatory Changes Across India's Pharma and Medical Device Sectors

India's CDSCO has issued numerous critical regulatory updates, impacting drug formulations, medical devices, and animal health. These changes, including product restrictions, revised fees, and new import rules, necessitate immediate review by procurement, regulatory affairs, and supply chain leaders to maintain compliance and mitigate operational risks across the Indian market.

REGULATORY INTELLIGENCE
3d ago

ANSM Fines Novo Nordisk and Eli Lilly for GLP-1 Obesity Campaign Breaches, Novo Nordisk Explores Legal Challenge

France's ANSM has fined Novo Nordisk and Eli Lilly for obesity campaign breaches related to GLP-1 analogue misuse. This action underscores escalating regulatory scrutiny on high-demand drug marketing. Novo Nordisk is considering a legal challenge, signaling potential prolonged legal and reputational impacts for major pharmaceutical players in the European market.

REGULATORY INTELLIGENCE
4d ago

FDA Faces Pressure to Restrict Livestock Antibiotic Use: Major Commercial Implications for Chemical and Life Sciences

Over 60 organizations have petitioned the FDA to revoke approvals for antibiotic use in livestock for disease prevention and growth promotion. This action, driven by concerns over antibiotic resistance and its human health toll, signals potential significant regulatory shifts. Procurement, supply chain, and regulatory affairs leaders must prepare for market disruption and new compliance requirements.

REGULATORY INTELLIGENCE
4d ago

Germany Abandons Branded Pharmaceutical Price Reduction Plan Amid Industry Opposition

Germany has reversed its decision to implement a variable pricing structure aimed at reducing branded pharmaceutical costs, following significant criticism from drug manufacturers. This move signals a crucial win for pharmaceutical companies, preserving current revenue models and mitigating potential market access challenges in one of Europe's largest economies. Procurement and regulatory teams should reassess their German market strategies.

REGULATORY INTELLIGENCE
4d ago

Health Canada's Drug Product Database: A Critical Resource for Market Intelligence and Regulatory Compliance

Health Canada's Drug Product Database (DPD), last updated March 1, 2019, offers vital intelligence for market access and regulatory compliance. This comprehensive online tool allows stakeholders to query drug identification numbers (DINs), ATC codes, and company data. For procurement, regulatory, and business development executives, the DPD is indispensable for strategic planning and risk management within the Canadian pharmaceutical landscape.

REGULATORY INTELLIGENCE
4d ago

CDSCO Authorizes Oseltamivir Outlets: Clarifying India's Supply Channels for H1N1 Antivirals

India's CDSCO has published a list of authorized outlets for oseltamivir formulation, critical for H1N1 swine flu. This action clarifies legitimate supply channels for this Schedule X drug, signaling intensified regulatory oversight in India's pharmaceutical sector. Procurement and supply chain leaders must ensure compliance with these defined distribution networks to mitigate risks and maintain market access.

REGULATORY INTELLIGENCE
5d ago

Express Scripts, PCMA Challenge Tennessee's FAIR Rx Act: PBM Vertical Integration Under Threat

Express Scripts and the PCMA are challenging Tennessee's FAIR Rx Act, a law prohibiting PBMs from owning pharmacies and restricting mail-order services. This follows CVS Caremark's similar lawsuit. If upheld, the law, effective 2028, threatens to close PBM-affiliated pharmacies, disrupt national drug supply chains, and impede patient access, impacting hundreds of thousands. This legal battle signals escalating state-level pressure on PBM business models.

REGULATORY INTELLIGENCE
6d ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
6d ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

REGULATORY INTELLIGENCE
6d ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
6d ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
6d ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

ENTITY HUBS

Entities in this Brief

HF Acquisition
company hub
Open company hub
Extreme Blast 48h Antiperspirant Deodorant
molecule hub
Open molecule hub